Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 22

1578P - Effect of immune checkpoint inhibitors in metastatic gastric cancer: A real-world evidence study

Date

21 Oct 2023

Session

Poster session 22

Topics

Cell-Based Therapy;  Immunotherapy;  Cancer Research

Tumour Site

Gastric Cancer

Presenters

Francesco Puccetti

Citation

Annals of Oncology (2023) 34 (suppl_2): S852-S886. 10.1016/S0923-7534(23)01930-0

Authors

E. Mazza1, F. Puccetti2, G. Hernández-Ibarburu3, F. Rusconi3, N. liscia1, L.A. barbieri2, E. Treppiedi2, A. cossu2, R. rosati2, U. elmore2

Author affiliations

  • 1 Medical Oncology, IRCCS Ospedale San Raffaele, 20132 - Milan/IT
  • 2 Gastrointestinal Surgery, IRCCS Ospedale San Raffaele, 20132 - Milan/IT
  • 3 Trinetx Europe Nv, TriNetX Europe NV, 9830 - Sint-Martens-Latem/BE

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1578P

Background

Despite the beneficial findings from different clinical trials, targeted immunotherapy is still debated in advanced gastric cancer care. Immune checkpoint inhibitors (ICIs) of programmed cell death protein 1 (PD-1) have emerged as a promising therapeutic option, demonstrating clinical activity in gastric cancer. This study aims to analyze the impact of PD-1 inhibition overall survival of a large-scale series of patients treated for metastatic gastric cancer.

Methods

A retrospective study was designed by using TriNetX Platform for a large-scale search of patients with metastatic gastric cancer, who underwent immunotherapy at large healthcare organizations collaborating through TriNetX-mediated network at both European (EMEA collaborative group) and international (GLOBAL) levels. Propensity score matching was used to balance these cohorts against the cohort of metastatic gastric cancer patients not treated with PD-1 inhibitors, to remove possible confounding effect of age and gender. Kaplan Meier analysis was used to compare the 2-year overall survival of these two cohorts, after propensity score matching was used.

Results

From a total of 15.318 patients affected by metastatic gastric cancer, a cohort of 1.425 patients treated with PD-1 inhibitors was identified, including 1.372 from TriNetX healthcare organization network at a global level (TNX-GLOBAL) and 53 from the EMEA group (TNX-EMEA). When compared to the propensity score matched control patient’s cohort with no PD-1 treatment, anti-PD-1 treated patients had significantly better overall survival in both TNX-GLOBAL, 44.73% vs 41.26% (p<0.01), and in TNX-EMEA, 39.31% vs 21.47% (p<0.01).

Conclusions

The evidence from the present retrospective cohort study using real-world data from TNX-GLOBAL and TNX-EMEA collaborative networks created the unique opportunity to analyze a large-scale series of patients with metastatic gastric cancer. Positive effects of anti-PD-1-targeted therapy on survival of such a frail cohort demonstrated the clinical relevance of prevalence of PD-1 expression and supported the effectiveness of new therapies based on ICI's for metastatic disease. Given these results, further studies on the role of ICI’s also in perioperative setting are awaited.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

IRCCS Ospedale San Raffaele.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.